Axcelead is the first integrated drug discovery solutions provider in the pharmaceutical industry in Japan, having succeeded the unique and comprehensive capabilities of drug discovery from Takeda Pharmaceutical Company Limited: “Experienced Scientists”, “Cutting -edge Technology Platform”, and “Huge Historical Drug Discovery Data”, and started its business in 2017. Leveraging the proprietary capabilities — we discuss together, challenge together and solve the problems hand-in-hand with our clients in every aspect of drug discovery as “PRO (Partnership Research Organization)” — the best partner for drug discovery players, and contribute to the creation of innovative medicines to the world.
Achieve distinction in the Field of Drug Discovery — the “3 Betters” of Axcelead —
In order to determine the optimal drug discovery target, we validate both its potential for drug discovery and therapeutic hypothesis on a given disease.
In recent years, it is getting harder to discover promising targets and opportunities in drug discovery.We offer to expand the opprtunities utilizing various approaches of target search, identification and validation based on our broad biology platforms and rich experiences on drug discovery. incorporating an AI-based approach free from cognitive bias and the state-of-the-art wet techniques, such as CRISPR-Cas based Genome Editing.
After initially narrowing down a promising compound group that act on the target, our next step is to further optimize candidate compounds for development that have high activity, good pharmacological properties and pharmacokinetics profile, and a high level of safety to ensure only those targets worthy of development are selected.
Our huge and drug-likelibrary, consisting of over 1.5 million compounds, helps to support promising hit finding process. Furthermore, the rapid and high performance “compound design-synthesis-evaluation-analysis” cycle in lead generation/optimization process, refined in our days as a pharmaceutical company, is the key to successful ”candidate” generation.
While advancing IND applications is necessary, it is clear that being able to predict the appropriate dosage, pharmacokinetics and efficacy in clinical trials is an equally important.
We can offer the PK/PD modeling and simulation enabling rapid design of the clinical trial dose. Our scientists, who have succeeded in numerous projects to date, greatly increases the probability of successful clinical trials.
At Axcelead, completing studies specified by our clients is simply not enough. As your partner, we make every effort to ensure you achieve your project goals. Our experienced scientists, while always pursuing the 3 Betters, act as your guide and lead the way to the next step in drug discovery.
Solutions in terms of a specific research theme, stage or modality
Solutions for Individual Subjects
Axcelead offers the optimum solution in line with your research subject
Without entering into a confidential disclosure agreement (CDA), conduct an open discussion to allow the client to detail their current concerns and expectations without providing confidential information.
If necessary, a CDA will be entered into and then we will request detailed information regarding the target, etc. Later, we will introduce the solution that we can provide to the client.
Proposal & Quotation
Drawing upon our rich experience to date in the field of drug discovery a proposal and estimate will be furnished with the optimum solution in line with the client’s goals and expectations.
We will discuss detailed information including the scope of work, research scheme, and payment terms, and move toward the conclusion of a contract.
Initiate study or a project. We will establish regular briefing sessions and an environment of open discussion and aim to ensure the mutual sharing of information with clients in a timely manner while making certain any problems are quickly resolved.
A final report will be provided to the client that details the deliverables (reports, test data, and compounds, etc.) agreed to in the contract, the completion of same and thus represents the conclusion of the agreement.
We enjoy the patronage of over 100 facilities, including pharmaceutical companies, venture companies and academia